INCA33890: Clinical Trials

2 trials of INCA33890, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 not yet recruiting, 1 recruiting. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Not yet recruiting 1, Recruiting 1

Follow INCA33890: new trials by email Literature Review of INCA33890 trials Research Report on INCA33890

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Clinical Trial Comparing an Antibody (INCA33890) Versus Pembrolizumab for Squamous Cell Carcinoma of the Head and Neck.
INCA33890, Pembrolizumab - Head and Neck Cancer Squamous Cell Carcinoma
Phase 2Not yet recruitingGroupe Oncologie Radiotherapie Tete et Cou782027-02-012026-10-22
A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy
INCA33890 - CRC (Colorectal Cancer)
Phase 2RecruitingIncyte Corporation402026-12-142026-11-17

Conditions studied

Colonic Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Neoplasm, Residual (1)

Sponsors

Groupe Oncologie Radiotherapie Tete et Cou (1)  ·  Incyte Corporation (1)

Countries

Puerto Rico (1)  ·  United States (1)